Winton Group’s ANI Pharmaceuticals ANIP Stock Holding History

Winton Group’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.56M	Buy	+55,058	New	+$4.42M	0.15%	183
2021 Q4	–	Sell	-7,788	Closed	-$256K	–	1012
2021 Q3	$256K	Buy	7,788 +569	+8%	+$17.7K	0.01%	1157
2021 Q2	$253K	Sell	7,219 -898	-11%	-$30.5K	0.01%	1273
2021 Q1	$293K	Sell	8,117 -1,535	-16%	-$48.1K	0.02%	1152
2020 Q4	$280K	Sell	9,652 -17,752	-65%	-$508K	0.02%	1072
2020 Q3	$773K	Sell	27,404 -15,162	-36%	-$451K	0.03%	927
2020 Q2	$1.38M	Buy	+42,566	New	+$1.53M	0.04%	827
2019 Q4	–	Sell	-13,672	Closed	-$996K	–	1533
2019 Q3	$996K	Buy	13,672 +5,804	+74%	+$434K	0.01%	829
2019 Q2	$647K	Buy	7,868 +3,509	+81%	+$250K	0.01%	570
2019 Q1	$307K	Buy	+4,359	New	+$256K	0.01%	795
2018 Q3	–	Sell	-4,313	Closed	-$288K	–	1010
2018 Q2	$288K	Sell	4,313 -1,568	-27%	-$97.9K	0.01%	844
2018 Q1	$342K	Buy	+5,881	New	+$373K	0.01%	925

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's ANIP Position: Q2 2026 in Review

Winton Group opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 55,058 shares worth $4.56M. The stake represents 0.15% of the portfolio and ranks #183 among its holdings. This is a return to the name: Winton Group previously reported a position in ANIP as recently as Q3 2021.

Winton Group first reported a position in ANIP in Q1 2018 and has held it in 12 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Winton Group held 55,058 shares of ANI Pharmaceuticals worth $4.56M as of Q2 2026.
ANI Pharmaceuticals was a new Winton Group position in Q2 2026.
ANI Pharmaceuticals made up 0.15% of Winton Group's portfolio in Q2 2026, its #183 holding.
Winton Group first reported a position in ANI Pharmaceuticals in Q1 2018 and has held it in 12 quarters since.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.